/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jifeng Feng

Zhejiang Cancer Hospital(CN)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

498

Papers

33.7K

Citations

63

h-index

253

i10-index

Jifeng Feng is an academic researcher from Zhejiang Cancer Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer-related molecular mechanisms research. The author has an h-index of 63, co-authored 424 publications.

ORCID: 0000-0002-7979-2391

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cancer-related molecular mechanisms research Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

Papers by this author

works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · The Lancet · 2,108 citations

https://doi.org/10.1016/s0140-6736(19)32222-6

Luis Paz‐Ares Mikhail Dvorkin Yuanbin Chen Niels Reinmuth

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

2014 · Journal of Clinical Oncology · 616 citations

https://doi.org/10.1200/jco.2013.53.6136

Taroh Satoh Rui‐Hua Xu Hyun Cheol Chung Guoping Sun

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

2019 · The Lancet Oncology · 261 citations

https://doi.org/10.1016/s1470-2045(19)30164-0

Zefei Jiang Wei Li Xichun Hu Qingyuan Zhang

Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures

2022 · Cancer Cell International · 171 citations

https://doi.org/10.1186/s12935-022-02599-7

Bing Feng Jian Wu Bo Shen Feng Jiang

C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis

2022 · BMC Medicine · 171 citations

https://doi.org/10.1186/s12916-022-02506-x

Meng Zhu Zhimin Ma Xu Zhang Dong Hang

Research topics

topics

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Cancer-related molecular mechanisms research

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat